Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer.

ABSTRACT:

Purpose

Estrogen receptor (ER)-positive breast cancer is the most common subtype, accounting for approximately 80% of cases, with endocrine therapy as the standard postoperative treatment. However, despite risk-reducing therapies, the risk of recurrence remains substantial. Studies, including the POETIC trial, have demonstrated that low Ki67 levels following short-term neoadjuvant endocrine therapy (sNAET) are associated with a favorable prognosis. The objective of this study is to identify genes associated with the suppression of cell cycle progression by sNAET in postmenopausal patients with ER-positive/human epidermal growth factor receptor 2-negative breast cancer.

Methods

Ninety-seven tissue samples were collected and classified into groups based on Ki67 expression leve

SUBMITTER: Hidaka K 

PROVIDER: S-EPMC12031974 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature